Cargando…

Oral and dental health in Huntington‘s disease - an observational study

BACKGROUND: Only a few case reports and case series dealing with oral and dental health care are available in literature until now. The aim of the present pilot study was to determine the status of dental health in comparison to matched controls and to heighten the neurologists’ and dentists’ awaren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saft, Carsten, Andrich, Jürgen E, Müller, Thomas, Becker, Julia, Jackowski, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766132/ https://www.ncbi.nlm.nih.gov/pubmed/24138900 http://dx.doi.org/10.1186/1471-2377-13-114

Ejemplares similares

Time Processing in Huntington's Disease: A Group-Control Study
por: Beste, Christian, et al.
Publicado: (2007)

Error Processing in Huntington's Disease
por: Beste, Christian, et al.
Publicado: (2006)

Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease
por: Hansen, Wiebke, et al.
Publicado: (2005)

PGC-1alpha as modifier of onset age in Huntington disease
por: Taherzadeh-Fard, Elahe, et al.
Publicado: (2009)

No evidence of impaired gastric emptying in early Huntington‘s Disease
por: Saft, Carsten, et al.
Publicado: (2011)

Glutathione S-Transferase Ω 1 variation does not influence age at onset of Huntington's disease
por: Arning, Larissa, et al.
Publicado: (2004)

No association between polymorphisms in the BDNF gene and age at onset in Huntington disease
por: Mai, Maren, et al.
Publicado: (2006)

Age at onset of Huntington disease is not modulated by the R72P variation in TP53 and the R196K variation in the gene coding for the human caspase activated DNase (hCAD)
por: Arning, Larissa, et al.
Publicado: (2005)

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series
por: Saft, Carsten, et al.
Publicado: (2006)

Resurrection of sildenafil: potential for Huntington’s Disease, too?
por: Achenbach, Jannis, et al.
Publicado: (2022)

The Role of the Immune System in Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2013)

Music perception and movement deterioration in Huntington’s disease
por: Beste, Christian, et al.
Publicado: (2011)

Differential Diagnosis of Chorea—HIV Infection Delays Diagnosis of Huntington’s Disease by Years
por: Achenbach, Jannis, et al.
Publicado: (2021)

Phonatory Dysfunction as a Preclinical Symptom of Huntington Disease
por: Rusz, Jan, et al.
Publicado: (2014)

Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD
por: Achenbach, Jannis, et al.
Publicado: (2021)

Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort
por: Achenbach, Jannis, et al.
Publicado: (2022)

Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington’s Disease—Data from a Real World Cohort
por: Achenbach, Jannis, et al.
Publicado: (2021)

Altered third‐party punishment in Huntington's disease: A study using neuroeconomic games
por: Brüne, Martin, et al.
Publicado: (2020)

Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY
por: Orth, Michael, et al.
Publicado: (2011)

A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
por: Beste, Christian, et al.
Publicado: (2013)

Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington’s Disease
por: Achenbach, Jannis, et al.
Publicado: (2022)

Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic‐rigid motor subtypes in Huntington's disease
por: Achenbach, Jannis, et al.
Publicado: (2020)

Time will tell: Decision making in premanifest and manifest Huntington’s disease
por: Heim, Beatrice, et al.
Publicado: (2020)

No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset
por: Schmid, Rahel Dominique, et al.
Publicado: (2022)

Does arterial hypertension influence the onset of Huntington's disease?
por: Valcárcel-Ocete, Leire, et al.
Publicado: (2018)

NMDA receptor gene variations as modifiers in Huntington disease: a replication study
por: Saft, Carsten, et al.
Publicado: (2011)

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
por: Saft, Carsten, et al.
Publicado: (2023)

PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease
por: Taherzadeh-Fard, Elahe, et al.
Publicado: (2011)

Supracubital perineurioma misdiagnosed as carpal tunnel syndrome: case report
por: Saft, Carsten, et al.
Publicado: (2004)

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease
por: Lee, De-Hyung, et al.
Publicado: (2014)

Awareness and Knowledge of Rare Diseases in German Dentists, Dental Specialists and Oral and Maxillofacial Surgeons: A Country-Wide Survey
por: Benz, Korbinian, et al.
Publicado: (2022)

A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
por: Wojtecki, Lars, et al.
Publicado: (2015)

Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Corrigendum: Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy
por: Nguyen, Quang Tuan Rémy, et al.
Publicado: (2022)

Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study
por: Jacobs, M., et al.
Publicado: (2016)

Age-at-onset in Huntington disease
por: Orth, Michael, et al.
Publicado: (2011)

An Exploration of Latent Structure in Observational Huntington’s Disease Studies
por: Ghosh, Soumya, et al.
Publicado: (2017)

Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial
por: Gelderblom, Harald, et al.
Publicado: (2017)

Gait variability as digital biomarker of disease severity in Huntington’s disease
por: Gaßner, Heiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9237jbro7ga32m240elm357bl